Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

PURPOSE: Insulin-like growth factor 1 receptor signaling through upregulation of the stimulatory ligand IGF-II has been implicated in the pathogenesis of adrenocortical carcinoma. As there is a paucity of effective therapies, this dose expansion cohort of a phase 1 study was undertaken to determine...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Haluska, Paul, Worden, Frank, Olmos, David, Yin, Donghua, Schteingart, David, Batzel, Gretchen N., Luisa Paccagnella, M., de Bono, Johann S., Gualberto, Antonio, Hammer, Gary D.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2875253/
https://ncbi.nlm.nih.gov/pubmed/19649631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-009-1083-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars